|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COLEC11 |
Gene summary for COLEC11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COLEC11 | Gene ID | 78989 |
| Gene name | collectin subfamily member 11 | |
| Gene Alias | 3MC2 | |
| Cytomap | 2p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001867 | UniProtAcc | Q9BWP8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 78989 | COLEC11 | HCC1_Meng | Human | Liver | HCC | 1.36e-39 | -1.75e-02 | 0.0246 |
| 78989 | COLEC11 | cirrhotic3 | Human | Liver | Cirrhotic | 4.15e-02 | 4.39e-01 | 0.0215 |
| 78989 | COLEC11 | Pt13.b | Human | Liver | HCC | 1.64e-12 | 2.14e-01 | 0.0251 |
| 78989 | COLEC11 | Pt14.a | Human | Liver | HCC | 1.12e-03 | 2.35e-01 | 0.0169 |
| 78989 | COLEC11 | S014 | Human | Liver | HCC | 8.00e-33 | 1.70e+00 | 0.2254 |
| 78989 | COLEC11 | S015 | Human | Liver | HCC | 4.38e-32 | 2.07e+00 | 0.2375 |
| 78989 | COLEC11 | S016 | Human | Liver | HCC | 2.43e-48 | 1.95e+00 | 0.2243 |
| 78989 | COLEC11 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 5.11e-12 | 6.53e-01 | 0.02 |
| 78989 | COLEC11 | PTCwithHT_1 | Human | Thyroid | HT | 2.12e-02 | 4.24e-01 | 0.0238 |
| 78989 | COLEC11 | PTCwithHT_6 | Human | Thyroid | HT | 4.42e-19 | 8.66e-01 | 0.02 |
| 78989 | COLEC11 | PTCwithHT_8 | Human | Thyroid | HT | 2.61e-10 | 4.57e-01 | 0.0351 |
| 78989 | COLEC11 | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.21e-04 | 3.57e-01 | 0.0419 |
| 78989 | COLEC11 | PTCwithoutHT_7 | Human | Thyroid | PTC | 2.12e-02 | 4.56e-01 | 0.0381 |
| 78989 | COLEC11 | ATC13 | Human | Thyroid | ATC | 2.34e-18 | 3.47e-01 | 0.34 |
| 78989 | COLEC11 | ATC5 | Human | Thyroid | ATC | 4.42e-19 | 3.70e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
| GO:00022536 | Thyroid | HT | activation of immune response | 47/1272 | 375/18723 | 3.55e-05 | 7.40e-04 | 47 |
| GO:00069564 | Thyroid | HT | complement activation | 22/1272 | 130/18723 | 6.17e-05 | 1.16e-03 | 22 |
| GO:00069598 | Thyroid | HT | humoral immune response | 40/1272 | 317/18723 | 1.14e-04 | 1.86e-03 | 40 |
| GO:00197309 | Thyroid | HT | antimicrobial humoral response | 16/1272 | 122/18723 | 8.45e-03 | 4.82e-02 | 16 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414514 | Liver | Cirrhotic | Phagosome | 73/2530 | 152/8465 | 1.61e-06 | 1.78e-05 | 1.10e-05 | 73 |
| hsa0414515 | Liver | Cirrhotic | Phagosome | 73/2530 | 152/8465 | 1.61e-06 | 1.78e-05 | 1.10e-05 | 73 |
| hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| hsa0414531 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COLEC11 | SNV | Missense_Mutation | rs772894762 | c.757N>A | p.Glu253Lys | p.E253K | Q9BWP8 | protein_coding | tolerated(0.33) | possibly_damaging(0.481) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
| COLEC11 | SNV | Missense_Mutation | c.454N>G | p.Phe152Val | p.F152V | Q9BWP8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| COLEC11 | SNV | Missense_Mutation | rs747333394 | c.560N>A | p.Arg187His | p.R187H | Q9BWP8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| COLEC11 | SNV | Missense_Mutation | rs866636297 | c.613N>A | p.Ala205Thr | p.A205T | Q9BWP8 | protein_coding | tolerated(0.36) | benign(0.029) | TCGA-E2-A1IK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| COLEC11 | deletion | Frame_Shift_Del | novel | c.627delA | p.Ala210ProfsTer111 | p.A210Pfs*111 | Q9BWP8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| COLEC11 | SNV | Missense_Mutation | novel | c.445G>A | p.Glu149Lys | p.E149K | Q9BWP8 | protein_coding | tolerated(0.11) | benign(0.291) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| COLEC11 | SNV | Missense_Mutation | rs866636297 | c.613G>A | p.Ala205Thr | p.A205T | Q9BWP8 | protein_coding | tolerated(0.36) | benign(0.029) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| COLEC11 | SNV | Missense_Mutation | novel | c.143N>G | p.Ser48Cys | p.S48C | Q9BWP8 | protein_coding | deleterious(0.03) | probably_damaging(0.959) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| COLEC11 | SNV | Missense_Mutation | c.581N>T | p.Pro194Leu | p.P194L | Q9BWP8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| COLEC11 | SNV | Missense_Mutation | rs387907076 | c.652N>A | p.Gly218Ser | p.G218S | Q9BWP8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |